[1] |
Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa[J]. Exp Dermatol, 2008,17(7):553⁃568. doi: 10.1111/j.1600⁃0625.2008. 00723.x.
|
[2] |
COL7A1与PLEC双基因突变致大疱性表皮松解症一例国内首报[J]. 中华皮肤科杂志, 2020,53(4):275⁃278. doi: 10. 35541/cjd.20190576.
|
[3] |
Shinkuma S. Dystrophic epidermolysis bullosa: a review[J]. Clin Cosmet Investig Dermatol, 2015,8:275⁃284. doi: 10.2147/CCID.S54681.
|
[4] |
Mohammedi R, Mellerio JE, Ashton GH, et al. A recurrent COL7A1 mutation, R2814X, in British patients with recessive dystrophic epidermolysis bullosa[J]. Clin Exp Dermatol, 1999,24(1):37⁃39. doi: 10.1046/j.1365⁃2230.1999.00404.x.
|
[5] |
Ben Brick AS, Laroussi N, Mesrati H, et al. Mutational founder effect in recessive dystrophic epidermolysis bullosa families from Southern Tunisia[J]. Arch Dermatol Res, 2014,306(4):405⁃411. doi: 10.1007/s00403⁃013⁃1421⁃y.
|
[6] |
Tamai K, Murai T, Mayama M, et al. Recurrent COL7A1 mutations in Japanese patients with dystrophic epidermolysis bullosa: positional effects of premature termination codon mutations on clinical severity. Japanese Collaborative Study Group on Epidermolysis Bullosa[J]. J Invest Dermatol, 1999,112(6):991⁃993. doi: 10.1046/j.1523⁃1747.1999.00601.x.
|
[7] |
Mellerio JE, Salas⁃Alanis JC, Talamantes ML, et al. A recurrent glycine substitution mutation, G2043R, in the type VII collagen gene (COL7A1) in dominant dystrophic epidermolysis bullosa[J]. Br J Dermatol, 1998,139(4):730⁃737. doi: 10.1046/j.1365⁃2133.1998.02496.x.
|
[8] |
Nagai M, Nagai H, Tominaga C, et al. Localised dominant dystrophic epidermolysis bullosa with a novel de novo mutation in COL7A1 diagnosed by next⁃generation sequencing[J]. Acta Derm Venereol, 2015,95(5):629⁃631. doi: 10.2340/00015555⁃2019.
|
[9] |
Lee JY, Li C, Chao SC, et al. A de novo glycine substitution mutation in the collagenous domain of COL7A1 in dominant dystrophic epidermolysis bullosa[J]. Arch Dermatol Res, 2000,292(4):159⁃163. doi: 10.1007/s004030050472.
|
[10] |
Murata T, Masunaga T, Shimizu H, et al. Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa[J]. Arch Dermatol Res, 2000,292(10):477⁃481. doi: 10.1007/s004030000162.
|
[11] |
Iwata T, Nakano H, Nakano A, et al. Dominant dystrophic epidermolysis bullosa caused by a novel G2037R mutation and by a known G2028R mutation in the type VII collagen gene (COL7A1)[J]. J Dermatol, 2006,33(8):550⁃556. doi: 10.1111/j.1346⁃8138.2006.00130.x.
|
[12] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015,17(5):405⁃424. doi: 10.1038/gim.2015.30.
|
[13] |
Almaani N, Liu L, Dopping⁃Hepenstal PJ, et al. Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa[J]. Acta Derm Venereol, 2011,91(3):262⁃266. doi: 10.2340/00015555⁃1053.
|
[14] |
Pfendner EG, Nakano A, Pulkkinen L, et al. Prenatal diagnosis for epidermolysis bullosa: a study of 144 consecutive pregnancies at risk[J]. Prenat Diagn, 2003,23(6):447⁃456. doi: 10.1002/pd.619.
|
[15] |
Chong SC, Hon KL, Yuen L, et al. Neonatal epidermolysis bullosa: lessons to learn about genetic counseling[J]. J Dermatolog Treat, 2021,32(1):29⁃32. doi: 10.1080/09546634. 2018.1527999.
|